Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05401565 · ClinicalTrials.gov registry record · Phase 2
Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT05401565 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 29 participants.
The verdict
NCT05401565, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults with PTSD.
Interventions
- DRUG Placebo
- DRUG Balovaptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2023-10-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05401565
The ClinicalTrials.gov registry entry for NCT05401565 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05401565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05401565 about?
NCT05401565 is a clinical study titled "Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)". This study will evaluate the efficacy and safety of 10 mg of oral administration balovaptan once a day (QD) compared with matching placebo in adults with PTSD.
What is the current status of trial NCT05401565?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2022-08-02. Estimated completion is 2023-10-05.
What interventions are being tested in trial NCT05401565?
The interventions under investigation include: Placebo (DRUG), Balovaptan (DRUG).
Who is sponsoring clinical trial NCT05401565?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.